Loading stock data…
IBRX
$7.28+0.11 (+1.53%)
Market OpenUpdated 3:44 PM EDT
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmunityBio, Inc. in the Healthcare sector is trading at $7.28. Wall Street consensus targets $13.00 (3 analysts), implying a +78.6% move over the next 12 months. The stock is currently 41% below its 52-week high of $12.43, remaining 46.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +78.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.28
Potential Downside
0%
Whystock Fair Value$7.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
98.22%
Volume
Today's trading volume
11.17M
Recent News
3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth
Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now
ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics License Application (sBLA) for ANKTIVA Plus BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer. The supplemental BLA was accepted for […]
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook
ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The update included the first substantial ANKTIVA data readout in non small cell lung cancer and new comparative data in non muscle invasive bladder cancer. These ASCO presentations expand the clinical picture for ANKTIVA across major solid tumor types beyond bladder cancer. For investors following...
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
ImmunityBio: Anktiva Explained and What Comes Next
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.